Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 18 | 2021 | 153 | 2.130 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 50 | 1.370 |
Why?
|
| Immunoglobulin G | 8 | 2022 | 71 | 1.330 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2018 | 15 | 0.940 |
Why?
|
| Antibody Formation | 2 | 2022 | 15 | 0.920 |
Why?
|
| Salivary alpha-Amylases | 1 | 2023 | 3 | 0.810 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.790 |
Why?
|
| Viral Vaccines | 1 | 2022 | 1 | 0.790 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 2017 | 7 | 0.770 |
Why?
|
| Agammaglobulinemia | 2 | 2018 | 2 | 0.720 |
Why?
|
| Common Variable Immunodeficiency | 2 | 2018 | 5 | 0.720 |
Why?
|
| Bacterial Infections | 3 | 2018 | 52 | 0.690 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 1 | 0.580 |
Why?
|
| Immunoglobulins | 1 | 2017 | 12 | 0.550 |
Why?
|
| Child, Preschool | 12 | 2019 | 597 | 0.540 |
Why?
|
| Immunologic Factors | 1 | 2017 | 26 | 0.540 |
Why?
|
| Immunotherapy | 1 | 2017 | 53 | 0.530 |
Why?
|
| Biomarkers | 6 | 2023 | 544 | 0.530 |
Why?
|
| Humans | 39 | 2023 | 25973 | 0.530 |
Why?
|
| Fluticasone | 4 | 2019 | 4 | 0.500 |
Why?
|
| Child | 12 | 2021 | 1217 | 0.470 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2019 | 106 | 0.430 |
Why?
|
| Glucocorticoids | 4 | 2019 | 63 | 0.420 |
Why?
|
| Precision Medicine | 3 | 2021 | 24 | 0.390 |
Why?
|
| Respiratory Sounds | 2 | 2019 | 9 | 0.370 |
Why?
|
| Bronchodilator Agents | 3 | 2019 | 11 | 0.350 |
Why?
|
| Female | 22 | 2021 | 14735 | 0.350 |
Why?
|
| Male | 21 | 2021 | 14280 | 0.350 |
Why?
|
| Adolescent | 9 | 2019 | 2100 | 0.340 |
Why?
|
| Adult | 13 | 2021 | 7666 | 0.330 |
Why?
|
| Salmeterol Xinafoate | 2 | 2019 | 2 | 0.320 |
Why?
|
| Alendronate | 2 | 2019 | 7 | 0.310 |
Why?
|
| Ibuprofen | 2 | 2021 | 11 | 0.300 |
Why?
|
| Middle Aged | 10 | 2021 | 8775 | 0.280 |
Why?
|
| NF-kappa B | 3 | 2022 | 114 | 0.280 |
Why?
|
| Double-Blind Method | 9 | 2021 | 393 | 0.280 |
Why?
|
| Young Adult | 6 | 2019 | 1942 | 0.270 |
Why?
|
| Saliva | 2 | 2023 | 48 | 0.270 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2018 | 31 | 0.260 |
Why?
|
| Administration, Inhalation | 7 | 2019 | 37 | 0.250 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 18 | 0.240 |
Why?
|
| Eosinophilia | 2 | 2017 | 36 | 0.220 |
Why?
|
| Cockroaches | 1 | 2003 | 2 | 0.210 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2003 | 4 | 0.210 |
Why?
|
| Allergens | 1 | 2003 | 16 | 0.210 |
Why?
|
| Acetaminophen | 3 | 2021 | 22 | 0.210 |
Why?
|
| Nucleocapsid | 1 | 2022 | 2 | 0.200 |
Why?
|
| Neutralization Tests | 1 | 2022 | 6 | 0.200 |
Why?
|
| beta-Glucans | 1 | 2022 | 26 | 0.190 |
Why?
|
| Sputum | 2 | 2019 | 21 | 0.190 |
Why?
|
| Health Personnel | 1 | 2022 | 87 | 0.190 |
Why?
|
| Pandemics | 2 | 2021 | 211 | 0.180 |
Why?
|
| Infant | 6 | 2018 | 495 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2019 | 1702 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2021 | 60 | 0.170 |
Why?
|
| Lung | 2 | 2019 | 157 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2021 | 1806 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 32 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 3 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2020 | 46 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 273 | 0.160 |
Why?
|
| Tiotropium Bromide | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mometasone Furoate | 1 | 2019 | 7 | 0.160 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 3 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 70 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 36 | 0.150 |
Why?
|
| Vitamin A Deficiency | 1 | 2018 | 1 | 0.150 |
Why?
|
| Contrast Sensitivity | 1 | 2018 | 6 | 0.150 |
Why?
|
| Vitamin A | 1 | 2018 | 8 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1333 | 0.150 |
Why?
|
| Zinc | 1 | 2018 | 39 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 85 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 16 | 0.150 |
Why?
|
| Glutathione | 1 | 2018 | 23 | 0.140 |
Why?
|
| Arginine | 1 | 2018 | 17 | 0.140 |
Why?
|
| HIV Infections | 1 | 2022 | 434 | 0.140 |
Why?
|
| Leukotriene Antagonists | 1 | 2016 | 1 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3400 | 0.130 |
Why?
|
| Inhalation Exposure | 2 | 2008 | 5 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2022 | 901 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 473 | 0.130 |
Why?
|
| Azithromycin | 1 | 2015 | 2 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 24 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2015 | 50 | 0.120 |
Why?
|
| Research Design | 3 | 2021 | 183 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 3 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 6 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 10 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 300 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 870 | 0.100 |
Why?
|
| Quality of Life | 1 | 2017 | 605 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 367 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 329 | 0.100 |
Why?
|
| Cotinine | 2 | 2011 | 5 | 0.100 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2023 | 8 | 0.100 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 5 | 0.090 |
Why?
|
| Pruritus | 1 | 2011 | 10 | 0.090 |
Why?
|
| Silicones | 1 | 2011 | 10 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 21 | 0.090 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 26 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2011 | 27 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1758 | 0.090 |
Why?
|
| Inflammation | 2 | 2022 | 267 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 433 | 0.080 |
Why?
|
| Aged | 3 | 2018 | 8732 | 0.080 |
Why?
|
| Smoking | 1 | 2011 | 180 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 65 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 6 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2021 | 572 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2019 | 61 | 0.070 |
Why?
|
| Albuterol | 2 | 2018 | 15 | 0.070 |
Why?
|
| Models, Biological | 1 | 2008 | 318 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 851 | 0.060 |
Why?
|
| Quinolines | 1 | 2005 | 8 | 0.060 |
Why?
|
| Acetates | 1 | 2005 | 16 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 729 | 0.060 |
Why?
|
| Air Pollution, Indoor | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pyroglyphidae | 1 | 2003 | 2 | 0.050 |
Why?
|
| Skin Tests | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cats | 1 | 2003 | 28 | 0.050 |
Why?
|
| Urban Health | 1 | 2003 | 22 | 0.050 |
Why?
|
| Child Welfare | 1 | 2003 | 16 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 103 | 0.050 |
Why?
|
| Dogs | 1 | 2003 | 151 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2022 | 437 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2022 | 2 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 45 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 5 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 41 | 0.050 |
Why?
|
| Syk Kinase | 1 | 2022 | 12 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 51 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemokines | 1 | 2002 | 18 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 8 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 20 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2021 | 19 | 0.050 |
Why?
|
| United States | 2 | 2018 | 1990 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2021 | 57 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 117 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 10 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 18 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 12 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 5 | 0.040 |
Why?
|
| Complement Activation | 1 | 2021 | 8 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2021 | 7 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2021 | 24 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 16 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2021 | 31 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 181 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2014 | 104 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 34 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 26 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 10 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 649 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 49 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 1107 | 0.040 |
Why?
|
| Ornithine | 1 | 2018 | 1 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 1 | 0.040 |
Why?
|
| Growth | 1 | 2018 | 6 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 648 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 17 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 10 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 9 | 0.030 |
Why?
|
| Chicago | 2 | 2011 | 898 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 34 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 95 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 3503 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 174 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 291 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 53 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 160 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 152 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 655 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 395 | 0.030 |
Why?
|
| Patch Tests | 1 | 2011 | 2 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 11 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 51 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 251 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2009 | 19 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 11 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 6 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 125 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 294 | 0.020 |
Why?
|
| Sulfides | 1 | 2005 | 10 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2005 | 13 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 16 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 65 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2002 | 14 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 7 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 129 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 64 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 34 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 66 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 543 | 0.010 |
Why?
|